<DOC>
	<DOCNO>NCT00255502</DOCNO>
	<brief_summary>This 52-week , multicenter , open-label study determine safety , tolerability pharmacokinetics TOPROL-XL ( metoprolol succinate ) extended-release tablet ( metoprolol CR/XL ) hypertensive pediatric subject . The study population include school age child ( age 6 12 year &lt; Tanner Stage 3 ) adolescent ( &gt; 12 year old &gt; Tanner Stage 3 16 year old ) gender . Because response therapy adult hypertension appear different black non-black population , recruitment mixture black non-black subject . Pharmacokinetic measurement perform subset patient . Thirty subject ( 15 subject 6 12 year age group 13 16 year age group ) series blood sample draw . All subject trough plasma level take 24 hour last dose open-label metoprolol CR/XL ( Visit 18 ) exception subject complete Protocol 307B ( 16 week open-label treatment ) .</brief_summary>
	<brief_title>307B - Safety , Tolerability Pharmacokinetics Study TOPROL-XL® Hypertensive Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Male female age 6 16 year inclusive time screen . Have negative urine pregnancy test , female childbearing potential . Have sign inform consent parent legal guardian assent form sign subject ( applicable ) . Have hypertension either : 1 . Have successfully complete Protocol 307A , , 2 . Have drop Protocol 307A fail screen Protocol 307A sit SBP/DBP great 20/10 mm Hg 95 th percentile use height adjust chart age gender ( see Appendices B E inclusive ) , 3 . Have enrol Protocol 307A meet screen criterion Protocol 307B enrol site already randomize 6 subject Protocol 307A . Have ability swallow tablet . Have secondary hypertension due coarctation aorta , pheochromocytoma , hyperthyroidism Cushing ’ syndrome . Have heart rate &lt; 55 beat per minute Visit 1 . Have history asthma and/or recur pulmonary disease infection . Have history cystic fibrosis . Have know hypersensitivity reaction betablockers . Have know bleeding , coagulation platelet disorder interfere blood sampling . Have history Insulin Dependent Diabetes Mellitus . Be situation condition , opinion investigator sponsor , may interfere participation study produce significant risk subject interfere assessment safety efficacy endpoint . Have receive investigational agent therapeutic reason within 30 day prior receive study medication . Have clinically significant cardiac valvular disease . Have diagnosis heart failure . Have clinically significant arrhythmia . This define arrhythmia require medical therapy cause symptom . Atrioventricular ( AV ) conduction disturbance , ie , second third degree AV block . Be unable unwilling comply study requirement . Be noncompliant singleblind placebo runin period study define miss three dos study visit . Have impair liver function define either acute liver disease chronic liver disease persistent liver enzyme value great one one half time upper limit normal range AST ALT . Have know history bilateral renal artery stenosis , unilateral renal artery stenosis single kidney . Nephrotic subject remission exclude . Be pregnant breastfeeding infant . Currently take medication know inhibit CYP2D6 , quinidine , fluoxetine , paroxetine propafenone . Currently take catecholaminedepleting medication reserpine . For subject currently take medication know inhibit CYP2D6 catecholaminedepleting medication , sponsor must contact assess feasibility inclusion study . Currently take selective serotonin reuptake inhibitor ( SSRIs ) atypical antipsychotic medication . Have history alcohol drug abuse , positive urine screen drug abuse alcohol .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Pediatric hypertension</keyword>
</DOC>